ACADIA Pharmaceuticals Inc. (ACAD) and Spero Therapeutics Inc. (NASDAQ:SPRO) Comparison side by side

As Biotechnology companies, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Spero Therapeutics Inc. (NASDAQ:SPRO) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals Inc. 207.80M 14.85 248.57M -1.44 0.00
Spero Therapeutics Inc. 3.27M 54.93 45.83M -3.06 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of ACADIA Pharmaceuticals Inc. and Spero Therapeutics Inc.


Table 2 demonstrates the return on assets, return on equity and net margins of ACADIA Pharmaceuticals Inc. and Spero Therapeutics Inc.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals Inc. -119.62% -88.2% -75.5%
Spero Therapeutics Inc. -1,401.53% -52.4% -47.8%


The Current Ratio and Quick Ratio of ACADIA Pharmaceuticals Inc. are 6.1 and 6 respectively. Its competitor Spero Therapeutics Inc.’s Current Ratio is 13 and its Quick Ratio is 13. Spero Therapeutics Inc. can pay off short and long-term obligations better than ACADIA Pharmaceuticals Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for ACADIA Pharmaceuticals Inc. and Spero Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ACADIA Pharmaceuticals Inc. 0 3 3 2.50
Spero Therapeutics Inc. 1 0 0 1.00

ACADIA Pharmaceuticals Inc. has a 26.49% upside potential and an average target price of $27.17. Competitively the average target price of Spero Therapeutics Inc. is $9, which is potential -13.71% downside. The results provided earlier shows that ACADIA Pharmaceuticals Inc. appears more favorable than Spero Therapeutics Inc., based on analyst belief.

Insider and Institutional Ownership

The shares of both ACADIA Pharmaceuticals Inc. and Spero Therapeutics Inc. are owned by institutional investors at 86.7% and 59.8% respectively. Insiders held roughly 0.1% of ACADIA Pharmaceuticals Inc.’s shares. Comparatively, Spero Therapeutics Inc. has 0.5% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ACADIA Pharmaceuticals Inc. -1.47% -6.1% 34.62% 5.09% -37.59% -37.63%
Spero Therapeutics Inc. -17.85% -22.13% -36.6% -41.77% -36.06% -42.81%

For the past year ACADIA Pharmaceuticals Inc. has stronger performance than Spero Therapeutics Inc.


ACADIA Pharmaceuticals Inc. beats on 7 of the 12 factors Spero Therapeutics Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.